Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

Objective Response Rate (ORR) reported for bezuclastinib combination compared to 26% ORR for sunitinib monotherapy (p<0.0001) Safety profile of bezuclastinib combination was well tolerated with no ...
The Chronicle of Higher EducationOpinion

The Decline of the Great American Research University

They still talk about their commitment to excellence, their great achievements, their leadership of the world of science, but ...

Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript

Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...
Sunday Trust on MSN

Where Is The Money?

Since May 2023, the President Bola Ahmed Tinubu administration has introduced sweeping economic reforms that have seen government revenues hit a record high. From billions of dollars saved from the ...